Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30580699 | 0.83 | HSD11B1 (0.37) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL27422130 | 0.78 | OPRM1 (0.34) | — | |
| SCHEMBL7458612 | 0.78 | OPRM1 (0.34) | — | |
| SCHEMBL7806789 | 0.78 | SLC6A3 (0.44) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL7993777 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL4781128 | 0.77 | HSD11B1 (0.34) | SLC6A4 | |
| SCHEMBL27422134 | 0.77 | HSD11B1 (0.34) | SLC6A4 | |
| SCHEMBL8812050 | 0.77 | OPRM1 (0.36) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4669798 | 0.75 | OPRK1 (0.38) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6574843 | 0.69 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453511-A1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH A/S (DK) | 2004-09-08 | — | — | EP | claimed |
| WO-2003045388-A1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| EP-1940404-A2 | PHARMACEUTICAL COMPOSITION COMPRISING 2,3-DISUBSTITUTED TROPANES FOR THE TREATMENT OF DISORDERS OF SEXUAL DESIRE | Boehringer Ingelheim International GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028770-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS FOR NEUROPROTECTION IN PATIENTS SUFFERING FROM AN ADVANCED STAGE OF A MENTAL DISEASE | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028769-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR NEUROPROTECTION | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| EP-1755602-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR THE INHIBITION OF BETA-AMYLOID (A BETA 40 AND A BETA 42) GENERATION | NEUROSEARCH A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007006738-A2 | PHARMACEUTICAL COMPOSITION COMPRISING 2 , 3-DISUBSTITUTED TROPANES FOR THE TREATMENT OF DISORDERS OF SEXUAL DESIRE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1727547-A1 | COMPOUNDS FOR THE SUSTAINED REDUCTION OF BODY WEIGHT | NEUROSEARCH A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| EP-1708706-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND A DOPAMINE AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1708707-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ANTAGONIST | NEUROSEARCH A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| EP-1675591-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | NEUROSEARCH A/S (DK) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005039580-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1429811-A1 | THEURAPEUTIC TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1397358-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003015830-A1 | THEURAPEUTIC TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002102801-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| US-6395748-B2 | Use treating Alzheimer's disease; monoamine reuptake inhibitor tropanes such as tesofensine (2-methoxymethyl-3-(3,4-dichlorophenyl)-tropane) | NEUROSEARCH A/S (DK) | 2002-05-28 | — | — | US | disclosed |
| US-6288079-B1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS; NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, SLEEP, AND BRAIN DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; TESOFENSINE (2-ethoxymethyl-3-(3,4-dichlorophenyl)-tropane) | NEUROSEARCH A/S (DK) | 2001-09-11 | — | — | US | disclosed |
| EP-0885220-A1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030997-A1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-08-28 | — | — | WO | disclosed |